SSG
PTLA

Summit Securities Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Summit Securities Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-500
Closed -$12K – 600
2013
Q2 		$12K Buy
+500
New +$9.94K 0.01% 297

Other funds holding PTLA

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Summit Securities Group's PTLA Position: Q3 2013 in Review

Summit Securities Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2013, closing a stake of 500 shares — an estimated $12K sold.

Summit Securities Group first reported a position in PTLA in Q2 2013 and held it in 1 quarter. The position peaked at $12K in Q2 2013. 69 funds tracked by Wall St. Rank hold PTLA as of Q3 2013.

  • Summit Securities Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 500 Portola Pharmaceuticals, Inc. shares in Q3 2013, an estimated $12K.
  • Summit Securities Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's Portola Pharmaceuticals, Inc. position peaked at $12K in Q2 2013.
  • 69 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.